Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.

about

Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.

P2860

Q38826494-5199C83D-BA14-4B86-B799-9BF3462A2061 Q50426810-7209F4D5-D9BD-4C8E-BB28-AD7929B72A06

P2860

Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.

Item

http://www.wikidata.org/entity/Q38796480

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Effective Concentration of a M ...... tant Chronic Myeloid Leukemia.

@en

type

Item

label

Effective Concentration of a M ...... tant Chronic Myeloid Leukemia.

@en

prefLabel

Effective Concentration of a M ...... tant Chronic Myeloid Leukemia.

@en

P1476

Effective Concentration of a M ...... tant Chronic Myeloid Leukemia.

@en

P2093

Chaofeng Mu

http://www.w3.org/2001/XMLSchema#string

Guodong Zhang

http://www.w3.org/2001/XMLSchema#string

Haifa Shen

http://www.w3.org/2001/XMLSchema#string

Helen Ma

http://www.w3.org/2001/XMLSchema#string

Jianliang Shen

http://www.w3.org/2001/XMLSchema#string

Junhua Mai

http://www.w3.org/2001/XMLSchema#string

Ralph B Arlinghaus

http://www.w3.org/2001/XMLSchema#string

Tong Sun

http://www.w3.org/2001/XMLSchema#string

Wenjing Tao

http://www.w3.org/2001/XMLSchema#string

Xiaojun Xia

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.

P304

899-910

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-15-0577-T

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26846820

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

5065108

http://www.w3.org/2001/XMLSchema#string

Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.

about

P2860

P2860

Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932